Elutia Inc. (ELUT)
- Previous Close
3.8100 - Open
3.7248 - Bid --
- Ask --
- Day's Range
3.7000 - 3.9900 - 52 Week Range
1.1400 - 5.2400 - Volume
20,042 - Avg. Volume
55,617 - Market Cap (intraday)
129.429M - Beta (5Y Monthly) 0.73
- PE Ratio (TTM)
-- - EPS (TTM)
-3.0900 - Earnings Date Nov 4, 2024 - Nov 8, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.00
Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
elutia.comRecent News: ELUT
View MoreResearch Reports: ELUT
View MorePerformance Overview: ELUT
Trailing total returns as of 10/3/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ELUT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ELUT
View MoreValuation Measures
Market Cap
129.43M
Enterprise Value
134.05M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.39
Price/Book (mrq)
--
Enterprise Value/Revenue
5.36
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-261.08%
Return on Assets (ttm)
-29.16%
Return on Equity (ttm)
--
Revenue (ttm)
24.99M
Net Income Avi to Common (ttm)
-70.09M
Diluted EPS (ttm)
-3.0900
Balance Sheet and Cash Flow
Total Cash (mrq)
18.19M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
490.12k